+ Part of the HMP Communications
Cardiovascular Network
An Innovation Adventure — From JHU Design Day to Stanford Biodesign to Heart Rhythm
On May 7th, I met my design team in Baltimore at Design Day at the Center for Bioengineering Innovation and Design at Johns Hopkins University (JHU). Since graduating from medical school in 1985, Johns Hopkins had changed. At the time there was a single modern building for the medical school classes, the older hospital, dorms, and the Cooley Center (named after Dr. Denton Cooley himself). Now the old historic building was surrounded by a myriad of major modern buildings and complexes. Our meeting was in the Armstrong Building, and we were wowed by the accomplishments of undergraduate and graduate innovators in both engineering and business. There were also many medical devices with US and global implications: "Oh youth, they have products that could change the world and even save the global economy while doing it!"
EuroPCR: PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent
EuroPCR: PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent
NATICK, Mass., May 18, 2012 — Boston Scientific Corporation announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm Promus Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent System in treating de novo coronary lesions in small coronary vessels. Analysis of the data was presented today at the annual EuroPCR Scientific Program in Paris.
SCAI: Study Identifies Unnecessary Surgeries Due to Induced Vasospasm
NEWARK, Del., May 17, 2012 -- Research led by Christiana Care Health System's Andrew Doorey, MD, has found that a small number of patients mistakenly undergo bypass surgery after diagnostic angiography.
SCAI: Study Identifies Unnecessary Surgeries Due to Induced Vasospasm
NEWARK, Del., May 17, 2012 -- Research led by Christiana Care Health System's Andrew Doorey, MD, has found that a small number of patients mistakenly undergo bypass surgery after diagnostic angiography.
The findings – presented May 10 in in Las Vegas during the Society for Cardiovascular Angiography and Interventions' annual meeting – could determine a new way of clinical practice that could save patients from unnecessary operations and reduce health care costs.
The findings showed that some patients are erroneously diagnosed with having stenosis when they in fact have experienced a vasospasm.
"There is a difficulty in distinguishing a temporary blockage from a fixed blockage because both look identical," said Doorey, the study's principal investigator and a cardiologist with Christiana Care Cardiology Consultants. "But the problem of the vasospasm in the critical left main artery has never been reported before and now for the first time we're bringing it to light."
EuroPCR: Women Undergoing TAVR Using the Medtronic CoreValve System Have Similar Survival Benefit as Men
Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
EuroPCR: Women Undergoing TAVR Using the Medtronic CoreValve System Have Similar Survival Benefit as Men
Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
PARIS – MAY 17, 2012 – Medtronic, Inc. announced new results from the CoreValve ADVANCE Study, which found that women and men benefitted similarly from the CoreValve® System. The study, presented at EuroPCR 2012, evaluated patients who were at high-risk for surgical aortic valve replacement. The Medtronic CoreValve System is currently limited to investigational use in the United States.
The gender analysis, a secondary-endpoint evaluation in the real-world CoreValve ADVANCE Study, found that survival rates were nearly identical between genders, with no statistical differences in 30-day and 6-month all-cause mortality, cardiovascular mortality or the 30-day MACCE endpoint (major adverse cardiac & cerebrovascular events, a composite of all-cause mortality, myocardial infarction, emergent cardiac surgery or percutaneous re-intervention, and stroke).
EuroPCR: FAME II Trial Demonstrates the Importance of Targeting Treatment to the Right Patients
May 16, 2012 — A groundbreaking international trial, presented yesterday at EuroPCR, has demonstrated for the very first time the true value of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease.
EuroPCR: FAME II Trial Demonstrates the Importance of Targeting Treatment to the Right Patients
May 16, 2012 — A groundbreaking international trial, presented yesterday at EuroPCR, has demonstrated for the very first time the true value of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease. The study highlights the critical importance of targeting these interventions to patients with ischemia and may revolutionize the patient selection procedure for PCI.
The FAME II study is the first of its kind and has shown that targeting fractional flow reserve (FFR)-guided PCI and optimal medical treatment (OMT) to patients with ischemia (having at least one stenosis with FFR ≤ 0.80) can reduce the need for revascularization by a factor of between 6 - 11 compared with OMT alone. This study also provides clear evidence that patients without ischemia do not need to undergo PCI and can be successfully managed using OMT alone.
EuroPCR: Life-Saving Primary PCI Rising in 'Stent for Life' Countries
Paris, 16 May 2012: Life-saving primary percutaneous coronary intervention (PPCI) treatment is increasing in countries participating in the Stent for Life Initiative.
EuroPCR: Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries
New Randomized Controlled Trial Results Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
PARIS –– May 15, 2012 –– As EuroPCR 2012 gets under way today, Medtronic, Inc., announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved ind
Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation
Study Shows Promising Future Treatment for Heart Failure: New Heart Muscle From Stem Cells
May 15, 2012 — Durham, NC – A Japanese research team has developed a promising new treatment for heart failure by growing sheets of new heart muscle tissue from stem cells. When implanted in damaged rat hearts, the bioengineered tissue improved heart function.
Study Shows Promising Future Treatment for Heart Failure: New Heart Muscle From Stem Cells
May 15, 2012 — Durham, NC – A Japanese research team has developed a promising new treatment for heart failure by growing sheets of new heart muscle tissue from stem cells. When implanted in damaged rat hearts, the bioengineered tissue improved heart function.
The study, led by Dr. Kenji Miki, a cardiovascular surgeon at Osaka University Graduate School of Medicine, appears in the May issue of STEM CELLS Translational Medicine.
Miki’s team removed adult stem cells from 30 female mice and genetically modified them to mimic embryonic stem cells. They then used the modified stem cells to grow sheets of healthy heart muscle tissue and implanted them into rats with damaged heart muscle.
The implanted tissue sheets survived for four weeks and the damaged hearts of the rats that received them began to heal, they found.
Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Three-Month Dual Anti-Platelet Therapy (DAPT) is Shortest Duration For Any Major Drug Eluting Stent in Europe
New Indication Supported by Data From More Than 10,000 Patients
Hospital Mortality Rates for Cardiovascular Revascularization Patients Varies Significantly by State
Patients can improve their chances of selecting a better than average hospital depending on the state where it is located
St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension
ST. PAUL, Minn. and PARIS – May 15, 2012 – St. Jude Medical, Inc. today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood pressure in patients with hypertension, or high blood pressure, that is resistant to medical therapy.
Cedars-Sinai Heart Institute Honors Harvard Cardiologist With New Prize in Heart Research
LOS ANGELES (May 15, 2012) – Cedars-Sinai Heart Institute is honoring Eugene Braunwald, MD, Distinguished Hersey Professor of Medicine at Harvard Medical School, with The Eliot Corday, MD, International Prize in Heart Research.
Henry Ford Hospital Names Director of New Structural Heart Disease Program: William O'Neill, MD
DETROIT, May 14, 2012 /PRNewswire/ -- William W. O'Neill, MD, has been appointed medical director of the new Center for Structural Heart Disease at Henry Ford Hospital.
He will begin his new position on July 31.